Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
04
03
2022
accepted:
05
07
2022
pubmed:
16
8
2022
medline:
21
3
2023
entrez:
15
8
2022
Statut:
ppublish
Résumé
The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy. Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.85 log IU as the infectious threshold and an assay with a 95% limit of detection (LOD) at 17 IU/mL, were used to assess the proportion of: (i) HEV-RNA-positive BDs that would remain undetected; and (ii) blood components associated with these undetected BDs with an HEV-RNA dose >3.85 log IU, considering 4 NAT options (Individual testing [ID], MP-6, MP-12, and MP-24). Of the 510,118 BDs collected during the study period, 510 (0.10%) were HEV-RNA-positive. Based on measurable VLs available in 388 cases, 1%, 15.2%, 21.8%, and 32.6% of BDs would theoretically pass undetected due to a VL below the LOD of ID, MP-6, MP-12, and MP-24 testing, respectively. All BDs associated with a potentially infectious blood component would be detected with ID-NAT while 13% of them would be undetected with MP-6, 19.6% with MP-12, and 30.4% with MP-24 depending on the plasma volume. No red blood cell (RBC) components with an HEV-RNA dose >3.85 log IU would enter the blood supply, regardless of the NAT strategy used. A highly sensitive ID-NAT would ensure maximum safety. However, an MP-based strategy can be considered given that: (i) the risk of transmission is closely related to the plasma volume of blood components; (ii) RBC are the most commonly transfused components and have a low plasma content; and (iii) HEV-RNA doses transmitting infection exceed 4 log IU. To minimise the potential risk associated with apheresis platelet components and fresh frozen plasma, less than 12 donations should be pooled using an NAT assay with a LOD of approximately 20 IU/mL.
Sections du résumé
BACKGROUND
The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy.
MATERIALS AND METHODS
Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.85 log IU as the infectious threshold and an assay with a 95% limit of detection (LOD) at 17 IU/mL, were used to assess the proportion of: (i) HEV-RNA-positive BDs that would remain undetected; and (ii) blood components associated with these undetected BDs with an HEV-RNA dose >3.85 log IU, considering 4 NAT options (Individual testing [ID], MP-6, MP-12, and MP-24).
RESULTS
Of the 510,118 BDs collected during the study period, 510 (0.10%) were HEV-RNA-positive. Based on measurable VLs available in 388 cases, 1%, 15.2%, 21.8%, and 32.6% of BDs would theoretically pass undetected due to a VL below the LOD of ID, MP-6, MP-12, and MP-24 testing, respectively. All BDs associated with a potentially infectious blood component would be detected with ID-NAT while 13% of them would be undetected with MP-6, 19.6% with MP-12, and 30.4% with MP-24 depending on the plasma volume. No red blood cell (RBC) components with an HEV-RNA dose >3.85 log IU would enter the blood supply, regardless of the NAT strategy used.
DISCUSSION
A highly sensitive ID-NAT would ensure maximum safety. However, an MP-based strategy can be considered given that: (i) the risk of transmission is closely related to the plasma volume of blood components; (ii) RBC are the most commonly transfused components and have a low plasma content; and (iii) HEV-RNA doses transmitting infection exceed 4 log IU. To minimise the potential risk associated with apheresis platelet components and fresh frozen plasma, less than 12 donations should be pooled using an NAT assay with a LOD of approximately 20 IU/mL.
Identifiants
pubmed: 35969132
pii: 2022.0052-22
doi: 10.2450/2022.0052-22
pmc: PMC10072995
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110-118Références
J Clin Med. 2020 Jan 24;9(2):
pubmed: 31991629
J Virol. 2017 Oct 27;91(22):
pubmed: 28878075
J Infect Dis. 2022 Nov 11;226(10):1753-1760
pubmed: 34865052
Curr Opin Infect Dis. 2019 Oct;32(5):475-481
pubmed: 31361659
Transfus Med Rev. 2019 Jul;33(3):146-153
pubmed: 31327668
Euro Surveill. 2017 Apr 20;22(16):
pubmed: 28449730
Lancet. 2014 Nov 15;384(9956):1766-73
pubmed: 25078306
Emerg Infect Dis. 2013 May;19(5):729-35
pubmed: 23647659
Blood. 2014 Jan 30;123(5):796-7
pubmed: 24482503
Transfus Clin Biol. 2014 Nov;21(4-5):162-6
pubmed: 25267205
Viruses. 2016 Aug 05;8(8):
pubmed: 27527210
World J Gastroenterol. 2020 Oct 7;26(37):5543-5560
pubmed: 33071523
Transfusion. 2021 Dec;61(12):3390-3401
pubmed: 34632593
J Clin Microbiol. 2012 Mar;50(3):897-902
pubmed: 22205792
J Hepatol. 2022 Jan;76(1):46-52
pubmed: 34461207
J Clin Virol. 2018 Aug;105:109-111
pubmed: 29957544
Transfus Med Hemother. 2019 Apr;46(2):95-103
pubmed: 31191195
Biochimie. 2017 Oct;141:70-79
pubmed: 28483690
J Clin Virol. 2009 Jan;44(1):74-7
pubmed: 18993112
Front Med (Lausanne). 2018 Feb 01;5:5
pubmed: 29450199
J Med Microbiol. 2015 Jul;64(7):752-758
pubmed: 25976003
Emerg Infect Dis. 2007 Apr;13(4):648-9
pubmed: 17561564
Emerg Infect Dis. 2022 Jan;28(1):157-165
pubmed: 34932460
Vox Sang. 2018 Nov;113(8):811-813
pubmed: 30318777
Front Microbiol. 2021 Apr 14;12:645020
pubmed: 33936003
Clin Infect Dis. 2013 Aug;57(4):e122-6
pubmed: 23667262
Transfusion. 2004 Jun;44(6):934-40
pubmed: 15157263
Transfus Clin Biol. 2017 Sep;24(3):176-181
pubmed: 28690036
Transfusion. 2017 Feb;57(2):280-288
pubmed: 28144952
J Med Virol. 2004 Nov;74(3):419-24
pubmed: 15368508
Emerg Infect Dis. 2014 Nov;20(11):1914-7
pubmed: 25340881